BioCentury
ARTICLE | Clinical News

Adcetris brentuximab vedotin: Phase II started

October 29, 2012 7:00 AM UTC

Seattle Genetics began an open-label, U.S. Phase II trial to evaluate Adcetris as monotherapy in about 20 newly diagnosed Hodgkin's lymphoma patients ages >=60 years. Adcetris has accelerated approval in the U.S. to treat Hodgkin's lymphoma and anaplastic large cell lymphoma (ALCL). In July, EMA's CHMP recommended conditional approval of an MAA from Takeda for Adcetris for relapsed or refractory CD30-positive Hodgkin's lymphoma following autologous stem cell transplant (ASCT) or following >=2 prior therapies when ASCT or multi-agent chemotherapy is not a treatment option. CHMP also recommended conditional approval of the product for relapsed or refractory systemic ALCL (see BioCentury, July 23). ...